CLAUDIA GOLDENSTEIN SCHAINBERG
Projetos de Pesquisa
Unidades Organizacionais
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
conferenceObject OBSERVATIONAL STUDY OF SWITCHING ANTI-TNF AGENTS IN ANKYLOSING SPONDYLITIS: EFFECTIVENESS AND PREDICTORS(2014) SAAD, C. G. S.; SHIMABUCO, A. Y.; RIBEIRO, A. C. M.; MORAES, J. C. B.; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.; GONCALVES, C.; BONFA, E.article 0 Citação(ões) na Scopus Reply to: Cardiovascular risk in psoriatic arthritis: should we focus on hypertension and diabetes only?(2014) FAVARATO, M. H.; GOLDENSTEIN-SCHAINBERG, C.article 31 Citação(ões) na Scopus Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis(2014) FAVARATO, M. H.; MEASE, P.; GONCALVES, C. R.; SAAD, C. Goncalves; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.Objective New evidence has lightened the linkage between psoriatic arthritis (PsA) and the development of atherosclerosis and cardiovascular disease (CVD). We aimed to describe the prevalence of cardiovascular events and associated risk factors among patients with PsA. Methods Retrospective evaluation of medical records from consecutive PsA patients who fulfilled the CASPAR criteria for PsA attending a specialised spondyloarthritis clinic at a single referral centre. CVD was defined based on the occurrence of coronary artery disease (CAD) or cerebrovascular ischaemic disease events. Results We evaluated 158 PsA patients, 48.7% females and 51.3% males, aged 53.7+/-13.9 yrs. Mean PsA duration was 13.7+/-8.9 yrs and polyarticular subtype affected 66(42%) patients. According to drug therapy, 85 (54%) were using NSAIDs and 21 (13%) low-dose prednisone; 32 (20%) were on anti-TNF agents, 94 (60%) metothrexate, 18 (11%) leflunomide, 13 (8%) sulfasalazine, 5 (3%) other immunossupressors and 4 (2.5%) were on chloroquine. Over half patients (87, 55%) had arterial hypertension (AH); 51 (32%) had dyslipidaemia (DLP), 38 (29%) hypertriglyceridaemia and 36(23%) diabetes mellitus (DM). Lipid profile was similar for both genders with mean total cholesterol= 186.5+/-38.6mg/dl, LDL=112.3+/-30.6 mg/dl, HDL=47.89+/-14.6 and triglycerides=127.4+/-65.6 mg/dl. Of note, 14% PsA patients have had CVD, namely cerebrovascular or coronary heart disease. Sex, age, disease duration, joint involvement subtype, disease activity, CRP and lipid levels were similar among patients with and without CVD. The prevalence of All (95% vs. 45%, p<0.001), DLP (75% vs. 27.7%, p<0.001) and DM (60% vs. 19%, p<0.001) were significantly greater in PsA patients who have had CVD compared to those without CVD, conferring an odds ratio of 21.0 for All and of 5.4 for DM. Conclusion The high prevalence of CVD in PsA patients is influenced by increased All and DM. Hence early recognition and specific treatment is mandatory in order to reduce the risk for CVD, avoiding early morbidity and mortality.conferenceObject LOW COST MINIMALIST SHOE AS A MECHANICAL TREATMENT FOR ALGO-FUNCTIONAL ASPECTS AND ANALGESIC MEDICINE INTAKE IN ELDERLY WOMEN WITH KNEE OSTEOARTHRITIS(2014) TROMBINI-SOUZA, F.; MATIAS, A.; YOKOTA, M.; SCHAINBERG, C.; FULLER, R.; SACCO, I. C.bookPart 0 Citação(ões) na Scopus Dermatomyositis in rheumatologist's view(2014) SCHAINBERG, C. G.; ADEDUNTAN, R.Dermatomyositis (DM) is a chronic idiopathic inflammatory systemic diseasecharacterized by muscle inflammation due to perivascular involvement, usually expressedby weakness; typical cutaneous inflammation may accompany, precede or follow themuscle complaint. DM can occur at any age. In general it is believed that juveniledermatomyositis (JDM), which occurs before age 18, encompass more vasculopathy andless autoantibodies compared to the disease that affects adults. For adults, the peakincidence is close to 50 years of age, there is a female predominance and it is estimatedthat the incidence of DM is close to 9.5 cases per million people. © 2015 by Nova Science Publishers, Inc. All rights reserved.conferenceObject INFLUENCE OF ALPHA 2 DO COLLAGEN V OVEREXPRESSION IN PHYSIOPHATOLOGY OF FIBROSIS SYSTEMIC SCLEROSIS PATIENTS(2014) MORAIS, J.; MARTIN, P.; VELOSA, A. P. P.; ANDRADE, P. C.; CRUZ, I. B.; MIRACCA, E. C.; FAC, F. A. C. Barrence; CARRASCO, S.; GOLDEINSTEIN-SCHAINBERG, C.; NAGAI, M. A.; PARRA, E. R.; CAPELOZZI, V. L.; TEODORO, W. R.conferenceObject HLA-B27 PREVALENCE IN A COHORT OF BRAZILIAN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS(2014) GOLDENSTEIN-SCHAINBERG, C.; CARRASCO, S.; SAAD, C. G.; MORAES, J. C. B.; GONCALVES, C. R.; SAMPAIO-BARROS, P.; PARRA, E. R.conferenceObject LONG-TERM EFFECT OF A FLEXIBLE MINIMALIST SHOE ON ALGO-FUNCTIONAL, ANALGESIC MEDICATION INTAKE AND GATT KINEMATIC IN ELDERLY WOMEN WITH KNEE OSTEOARTHRITIS(2014) MATIAS, A.; TROMBINI-SOUZA, F.; YOKOTA, M.; PEREIRA, I.; SCHAINBERG, C.; FULLER, R.; SACCO, I. C.conferenceObject SLEEP AND QUALITY OF LIFE IN PSORIATIC ARTHRITIS(2014) ARANCIBIA, L. A.; GONCALVES, C. R.; SAMPAIO, P. B.; GOLDENSTEIN-SCHAINBERG, C.conferenceObject LONG-TERM EVALUATION OF NT-ProBNP LEVELS IN ANKYLOSING SPONDYLITIS PATIENTS UNDER TNF BLOCKERS(2014) RUSSO, D. T.; MORAES, J. C. B.; SAAD, C. G. S.; RIBEIRO, A. C. M.; SCHAINBERG, C. G.; SAMPAIO-BARROS, P. D.; GONCALVES, C. R.; BONFA, E.